Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 12, 2010, Pages 1596-1602

  Perrin, F M R ^a,b   Woodward, N ^b   Phillips, P P J ^c   McHugh, T D ^a   Nunn, A J ^c   Lipman, M C I ^b   Gillespie, Stephen H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

BacT ALERT 3D mycobacteria detection systems; Chest CT; Chest X ray; Sputum mycobacterial load; Time to culture positivity

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LIQUID CULTURE; LUNG CAVITATION; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM; PRIORITY JOURNAL; SPUTUM ANALYSIS; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 78649372955     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Domínguez-Castellano A, Muniain M A, Rodriguez-Baño J, et al. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2003; 7: 432-438.
2. Gomes M, Saad Junior R, Stirbulov R. Pulmonary tuberculosis: relationship between sputum bacilloscopy and radiological lesions. Rev Inst Med Trop Sao Paulo 2003; 45: 275-281.
3. Greenbaum M, Beyt E, Murray P R. The accuracy of diagnosing pulmonary tuberculosis at a teaching hospital. Am Rev Respir Dis 1980; 121: 477-481.
4. Kim T C, Blackman R S, Heatwole K M, Kim T, Rochester D F. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis 1984; 129: 264-268.
5. Rathman G, Sillah J, Hill P C, et al. Clinical and radiological presentation of 340 adults with smear-positive tuberculosis in The Gambia. Int J Tuberc Lung Dis 2003; 7: 942-947.
6. Singla R, Osman M M, Khan N, Al-Sharif N, Al-Sayegh M O, Shaikh M A. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis 2003; 7: 58-64.
7. Telzak E E, Fazal B A, Pollard C L, Turett G S, Justman J E, Blum S. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997; 25: 666-670.
8. Epstein M D, Schluger N W, Davidow A L, Bonk S, Rom W N, Hanna B. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998; 113: 379-386.
9. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976; 2: 1102-1124.
10. Aber V R, Nunn A J. Factors affecting relapse following short-course chemotherapy. Bull Int Union Tuberc 1978; 53(4): 260-264.
11. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-534.
12. Darbyshire J H, Aber V R, Nunn A J. Predicting a successful outcome in short-course chemotherapy. Bull Int Union Tuberc 1984; 59: 22.
13. East African/British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am Rev Respir Dis 1981; 123: 165-170.
14. Zierski M, Bek E, Long M W, Snider D E Jr. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 1980; 122: 879-889.
15. Hatipoglu O N, Osma E, Manisali M, et al. High resolution computed tomographic findings in pulmonary tuberculosis. Thorax 1996; 51: 397-402.
16. Matsuoka S, Uchiyama K, Shima H, et al. Relationship between CT findings of pulmonary tuberculosis and the number of acid-fast bacilli on sputum smears. Clin Imaging 2004; 28: 119-123.
17. Allen B W, Mitchison D A. Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci 1992; 49: 94-98.
18. Canetti G. The tubercle bacillus in the pulmonary lesion of man. New York, NY, USA: Springer, 1955.
19. Gosling R D, Uiso L O, Sam N E, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-1345.
20. Mitchison D A, Sturm A W. The measurement of early bactericidal activity. In: Baillière T, ed. Baillière's clinical infectious diseases. London, UK: Baillière Tyndall, 1997: pp 185-206.
21. Drobniewski F A, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 3; 141-147:2003.
22. Wallis R S, Patil S, Cheon S H, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 2600-2606.
23. Palaci M, Dietze R, Hadad D J, et al. Cavitary disease and quantitative sputum bacillary load in pulmonary tuberculosis. J Clin Microbiol 2007; 45: 4064-4066.
24. Pheiffer C, Carroll N M, Beyers N, et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis 2008; 12: 792-798.
25. Joloba M L, Johnson J L, Namale A, et al. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 528-536.
26. Wallis R S, Perkins M D, Phillips M, et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 2000; 161: 1076-1080.
27. Simon G. Radiology in epidemiological studies and some therapeutic trials. BMJ 1966; 2: 491-494.
28. Altman D G. Practical statistics for medical research. London, UK: Chapman and Hall, 1991.
29. Xu R. Measuring explained variation in linear mixed effects models. Stat Med 2003; 22: 3527-3541.
30. Chang K C, Leung C C, Yew W W, Chan S L, Tam C M. Dosing schedules of six-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 1153-1158.
31. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
32. Mitchison D A. The action of anti-tuberculosis drugs in shortcourse chemotherapy. Tubercle 1985; 66: 219-225.
33. Johnson J L, Vjecha M J, Okwera A, et al. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiologic manifestations of pulmonary tuberculosis in Uganda. Int J Tuberc Lung Dis 1998; 2: 397-404.
34. Nahid P, Gonzalez L C, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206.
35. Breen R A, Miller R F, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193: 1437-1440.